Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
R Ruze, T Liu, X Zou, J Song, Y Chen, R Xu… - Frontiers in …, 2023 - frontiersin.org
The prevalence of obesity and diabetes mellitus (DM) has been consistently increasing
worldwide. Sharing powerful genetic and environmental features in their pathogenesis …
worldwide. Sharing powerful genetic and environmental features in their pathogenesis …
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Z Zheng, Y Zong, Y Ma, Y Tian, Y Pang… - … and Targeted Therapy, 2024 - nature.com
Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the …
A Gastaldelli, K Cusi, LF Landó, R Bray… - The lancet Diabetes & …, 2022 - thelancet.com
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized …
D Dahl, Y Onishi, P Norwood, R Huh, R Bray, H Patel… - Jama, 2022 - jamanetwork.com
Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …
Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials
MS Popoviciu, L Păduraru, G Yahya… - International journal of …, 2023 - mdpi.com
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …
growing global concern. These comorbidities include type 2 diabetes, hypertension …
[HTML][HTML] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
T Coskun, S Urva, WC Roell, H Qu, C Loghin… - Cell metabolism, 2022 - cell.com
With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …
weight management and metabolic health. Multireceptor agonists in development may …
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a …
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled …
Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …